Precision medicine in Type 2 Diabetes: Targeting SGLT2-inhibitor Treatment For Kidney Protection

Thijs T Jansz, Katherine G Young, Rhian Hopkins, Andrew P McGovern, Beverley M Shields, Andrew T Hattersley, Angus G Jones, Ewan R Pearson, Richard A Oram, John M Dennis MASTERMIND Consortium
doi: https://doi.org/10.1101/2024.09.01.24312905

Article Information

doi 
https://doi.org/10.1101/2024.09.01.24312905
History 
  • September 2, 2024.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Thijs T Jansz1,*,
  2. Katherine G Young1,
  3. Rhian Hopkins1,
  4. Andrew P McGovern1,
  5. Beverley M Shields1,
  6. Andrew T Hattersley1,
  7. Angus G Jones1,
  8. Ewan R Pearson2,
  9. Richard A Oram1,
  10. John M Dennis1 and
  11. MASTERMIND Consortium
  1. 1University of Exeter Medical School, University of Exeter, Exeter, UK
  2. 2Division of Molecular & Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
  1. ↵* Corresponding author; email: t.jansz{at}exeter.ac.uk
Back to top
Posted September 02, 2024.
Download PDF

Supplementary Material

Data/Code
Email
Precision medicine in Type 2 Diabetes: Targeting SGLT2-inhibitor Treatment For Kidney Protection
Thijs T Jansz, Katherine G Young, Rhian Hopkins, Andrew P McGovern, Beverley M Shields, Andrew T Hattersley, Angus G Jones, Ewan R Pearson, Richard A Oram, John M Dennis
medRxiv 2024.09.01.24312905; doi: https://doi.org/10.1101/2024.09.01.24312905
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area